| Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. | |
| | |
MedLine Citation:
|
PMID: 18819968 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Aspergillus fumigatus undergoes morphological transition throughout its growth and development. These changes have direct implications for the effectiveness of antifungal treatment. Here we report the in vitro antifungal activity of voriconazole, amphotericin B and caspofungin against three specific phases of multicellular development of A. fumigatus. METHODS: A. fumigatus conidia were propagated for 8, 12 and 24 h prior to antifungal challenge. The resultant activity of the three agents tested was determined using an XTT reduction assay to assess both endpoint and time-kill susceptibility profiles. RESULTS: Endpoint susceptibility testing demonstrated a time-dependent decrease in efficacy for all three antifungal agents as the complexity of the A. fumigatus hyphal structure developed. Overall, amphotericin B exhibited the best spectrum of activity at each phase of growth, but was comparable to voriconazole against germinated conidial growth (8 h). Later, both voriconazole and caspofungin were ineffective against complex mycelial structures (12 and 24 h). Time-kill studies demonstrated that amphotericin B was significantly more efficacious at reducing A. fumigatus metabolism than both voriconazole and caspofungin for all three growth phases examined, most notably after 1 h of drug exposure (P < 0.001). CONCLUSIONS: Overall, the data presented demonstrate that treatment of actively growing A. fumigatus cells with antifungal agents is more efficacious than treating mature structures in vitro. Amphotericin B was consistently more effective against each phase and displayed rapid effects, and therefore may be a suitable option for managing patient groups at risk from aspergillosis infections. |
| | |
Authors:
|
Eilidh Mowat; Sue Lang; Craig Williams; Elaine McCulloch; Brian Jones; Gordon Ramage |
Related Documents
:
|
3180708 - Further in vitro studies with oxiconazole nitrate. 8404918 - Haemophilus test medium versus mueller-hinton broth with lysed horse blood for antimicr... 8219508 - Antimicrobial susceptibility testing of actinomyces pyogenes: comparison of disk diffus... 7264838 - Philophthalmus gralli: chemosensitivity of miracidia. 18964928 - Determination of bromine, chlorine, sulphur and phosphorus in peat by x-ray fluorescenc... 18838098 - Chemical composition, antimicrobial and antioxidant activities of the essential oil and... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2008-09-26 |
Journal Detail:
|
Title: The Journal of antimicrobial chemotherapy Volume: 62 ISSN: 1460-2091 ISO Abbreviation: J. Antimicrob. Chemother. Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2008-11-17 Completed Date: 2009-01-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7513617 Medline TA: J Antimicrob Chemother Country: England |
Other Details:
|
Languages: eng Pagination: 1281-4 Citation Subset: IM |
Affiliation:
|
Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amphotericin B
/
pharmacology* Antifungal Agents / pharmacology* Aspergillus fumigatus / drug effects* Biofilms / drug effects* Echinocandins / pharmacology* Formazans / metabolism Humans Microbial Sensitivity Tests / methods Microbial Viability Mycelium / drug effects Oxidation-Reduction Pyrimidines / pharmacology* Spores, Fungal / drug effects Triazoles / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Antifungal Agents; 0/Echinocandins; 0/Formazans; 0/Pyrimidines; 0/Triazoles; 0/caspofungin; 0/voriconazole; 1397-89-3/Amphotericin B; 70709-62-5/1,5-bis(2-methoxy-4-nitro-5-sulfophenyl)-3-((phenylamino)carbonyl)formazan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: SmvA, and not AcrB, is the major efflux pump for acriflavine and related compounds in Salmonella ent...
Next Document: The European Antibiotic Awareness Day.